



4a. Official negotiated price (ex-factory) vs median Progression Free Survival (PFS), stratified by type of cancer (at least 2 indications for each cancer type). (24 drugs are included in the analysis: 21 with a single indication, two with two indications and one with three indication)



4b. Discounted price with additional compulsory rebates vs median Progression Free Survival (PFS), stratified by type of cancer (at least 2 indications for each cancer type). (24 drugs are included in the analysis: 21 with a single indication and three with 2 indications)



Progression Free Survival (PFS)